Literature DB >> 17674922

Imaging through opaque corneas using anterior segment optical coherence tomography.

Julian P S Garcia1, Patricia M T Garcia, Douglas E Buxton, Anthony Panarelli, Richard B Rosen.   

Abstract

BACKGROUND AND
OBJECTIVE: To investigate the capability of the prototype AC Cornea OCT (Ophthalmic Technologies Inc., Toronto, Ontario, Canada) for imaging eyes with opaque corneas. PATIENTS AND METHODS: More than 50 eyes of patients were included in the study.
RESULTS: The density of opacification influenced the ability of OCT to reveal anterior segment details. Imaging was limited by shadows cast by abnormal pigmentation or vascularity within the cornea. However, the system's unique coronal perspective capability was helpful in revealing occult spatial relationships.
CONCLUSIONS: The AC Cornea OCT is valuable for examining eyes with opaque corneas and provides cross-sectional and coronal views helpful in formulating specific management strategies.

Entities:  

Mesh:

Year:  2007        PMID: 17674922     DOI: 10.3928/15428877-20070701-07

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  3 in total

1.  Statistics of optical coherence tomography data from human retina.

Authors:  Norberto Mauricio Grzywacz; Joaquín de Juan; Claudia Ferrone; Daniela Giannini; David Huang; Giorgio Koch; Valentina Russo; Ou Tan; Carlo Bruni
Journal:  IEEE Trans Med Imaging       Date:  2010-03-18       Impact factor: 10.048

2.  Anterior segment optical coherence tomography in eye injuries.

Authors:  Edward Wylegala; Dariusz Dobrowolski; Anna Nowińska; Dorota Tarnawska
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-03       Impact factor: 3.117

3.  Anterior segment optical coherence tomography for the quantitative evaluation of the anterior segment following Boston keratoprosthesis.

Authors:  Joann J Kang; Norma Allemann; Thasarat S Vajaranant; Thasarat Vajaranant; Jose de la Cruz; Maria Soledad Cortina
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.